Riverain Technologies

The company's business model centers on providing these advanced software tools to healthcare providers, including hospitals and radiology groups, to improve diagnostic accuracy and workflow efficiency. Serving a global client base, Riverain Technologies has expanded its reach to countries such as New Zealand, Australia, Saudi Arabia, Spain, the United Kingdom, South Africa, Italy, and Belgium. Revenue is generated through the sale and deployment of its ClearRead software suites, which can be installed on-site or in the cloud. The company is venture capital-backed, having secured a significant $15 million Series A funding round in September 2019, led by Ping An Global Voyager Fund.

Riverain's core products are the ClearRead CT and ClearRead Xray software suites. These tools are powered by machine learning and advanced modeling to enhance the clarity of thoracic images. A key feature is the patented vessel and bone suppression technology, which removes obscuring structures like blood vessels, ribs, and clavicles from CT and X-ray images, providing an unimpaired view of the lungs. This allows radiologists to better detect, characterize, and measure various types of lung nodules, including solid, sub-solid, and ground glass, which may be signs of early-stage cancer. Clinical studies have demonstrated that the technology can reduce reading times by up to 36% while decreasing the number of missed actionable nodules by 29%. The solutions have received multiple FDA 510(k) clearances, underscoring their validation for clinical use.